Care in Multiple Sclerosis (MS)

a study on Multiple Sclerosis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco 5391959, California 5332921 and other locations
Dates
study started
study ends around
Principal Investigator
by Emmanuelle Waubant, MD, PhD
Headshot of Emmanuelle Waubant
Emmanuelle Waubant

Description

Summary

This study is structured around three main aims.

In Aim 1, investigators will conduct community-based participatory research (CBPR) to develop culturally tailored methods to assess childhood adversity in multiple sclerosis (MS).

Aim 2 will investigate the impact of childhood adversity on MS outcomes among individuals with relapsing-remitting MS (RRMS), among whom 70% belong to a group historically under-represented in MS research: Black, Hispanic, or poverty-impacted. Aim 2 procedures involve two visits that include a research blood draw and an MRI scan.

In Aim 3, investigators will conduct interviews and surveys to explore environmental and social factors affecting quality of life for minority MS patients.

Official Title

CARE in MS: Childhood Adversity Research Effort in MS

Keywords

Multiple Sclerosis

Eligibility

You can join if…

Open to people ages 18 years and up

Aim 1 -

  • aged ≥18-29 years
  • diagnosis of RRMS (Fulfill international criteria for relapsing remitting (RRMS))
  • 70% self-identifying as a Black, Hispanic, or poverty-impacted (up to 138% of the federal poverty level) individual,and
  • fluent in English or Spanish.

Aim 2 -

  • aged ≥18-29 years
  • diagnosis of RRMS (Fulfill international criteria for relapsing remitting (RRMS))
  • 70% self-identifying as a Black, Hispanic, or poverty impacted, and
  • fluent reading in English or Spanish
  • Pediatric onset MS (MS onset before age 18 and age at time of enrollment is 18-25) OR adult-onset MS (MS onset at age 18 or older and age at time of enrollment is 19-29)
  • Disease duration below 8 years

Aim 3 -

Aim 3 will enroll the first 20 participants from Aim 2 who meet the following criteria:

  • completed at least 80% of study data in the cross-sectional study/Aim 2.
  • a total of 70% must self-identify as Black, Hispanic, or meet criteria for poverty impacted.
  • interviews will be evenly split between participants with high (top quartile) and low (bottom quartile) of PROMIS-10 scores.

You CAN'T join if...

  • Primary or Secondary Progressive MS
  • Inability to consent.
  • MS relapse within 30 days prior to study entry
  • Other major neurologic or psychiatric illness

Locations

  • UCSF accepting new patients
    San Francisco 5391959 California 5332921 94158 United States
  • University of Colorado Denver accepting new patients
    Aurora 5412347 Colorado 5417618 80045 United States

Lead Scientist at UCSF

  • Emmanuelle Waubant, MD, PhD
    Dr Waubant trained as a neurologist in Toulouse, France. She continued her training as a neuroimmunology fellow in Dr Stephen Hauser’s UCSF laboratory, focusing on matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP), and their role in migration of lymphocytes through equivalents of the blood-brain barrier.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
NYU Langone Health
ID
NCT07011914
Study Type
Observational
Participants
Expecting 386 study participants
Last Updated
Contact us about this trial